Trial Profile

A Post-marketing Study Evaluating the Presence and Concentration of BRIUMVI in Breast Milk (PROVIDE)

Status: Recruiting

Phase of Trial: Phase IV

Latest Information Update: 11 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ublituximab (Primary)
Indications Multiple sclerosis
Focus Pharmacokinetics
Acronyms PROVIDE
Sponsors TG Therapeutics Inc

Most Recent Events

04 Jun 2025 Planned End Date changed from 28 Jun 2025 to 30 Jun 2026.
04 Jun 2025 Planned primary completion date changed from 28 Jun 2025 to 30 Jun 2026.
29 May 2024 According to TG Therapeutics media release, company announced the schedule of upcoming presentations highlighting study designs for post-marketing studies being undertaken for BRIUMVI (ublituximab-xiiy) in patients with relapsing forms of multiple sclerosis, at the 2024 Consortium of Multiple Sclerosis Centers annual meeting, being held May 29 to June 1, 2024, in Nashville, Tennessee.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com